Park Ha Biological Technology Co., Ltd. (BYAH) Fair Value 2026

BYAH · Household & Personal Products · 2026-08-27

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.7 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-27, Park Ha Biological Technology Co., Ltd. (BYAH) trades at $2.81. QOC: 2.7/10. Value Trap Risk: 0/100 (SAFE). 0/13 models active.

Key Facts

Ticker: BYAH
Price: $2.81
Quality Score: 2.7/10
Value Trap Risk: 0/100
Models Active: 0/13
Last Updated: 2026-08-27

Strength: 0 independent models provide multi-angle coverage

Risk: Below-average Quality Score of 2.7/10 signals weak fundamentals

What Fair Value Does Each Model Give BYAH?

0 Intrinsic Value Models vs. Current Price ($2.81)

Core Models (Unlocked)
Model	Fair Value	Upside

All Models Active

All 0 models are displayed above.

What Is Park Ha Biological Technology Co., Ltd. (BYAH) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Park Ha Biological Technology Co., Ltd. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About BYAH?

0 of 13 models are currently active for BYAH. See which stocks rank higher →

How Does BYAH Rank in Household & Personal Products?

Among 35 Household & Personal Products stocks, BYAH ranks #33 by Quality of Company score. CirclFi's QOC score of 2.7/10 evaluates 32 fundamental signals. A score of 2.7 signals below-average fundamentals.

The Household & Personal Products sector introduces analytical considerations specific to retail business businesses. For Park Ha Biological Technology Co., Ltd., metrics like store traffic trends provide important context that general-purpose valuation models may underweight.

Is BYAH a Value Trap?

CirclFi's Value Trap algorithm assigns BYAH a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Park Ha Biological Technology Co., Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Park Ha Biological Technology Co., Ltd. scores 2.7 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BYAH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Park Ha Biological Technology Co., Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Household & Personal Products Stocks Should You Also Analyze?

10 related Household & Personal Products stocks with 13-model coverage

ADTIAdapti, Inc.QOC 3.1 DSYBig Tree Cloud Holdings LimitedQOC 2.4 SKVISkinvisible, Inc.QOC 4.4 TANHTantech Holdings LtdQOC 1.4 GROVGrove Collaborative Holdings, Inc.QOC 4.7 IPARInterparfums, Inc.QOC 9.3 ELFe.l.f. Beauty, Inc.QOC 8.1 EPCEdgewell Personal Care CompanyQOC 7.4 HNSTThe Honest Company, Inc.QOC 6.1 PGThe Procter & Gamble CompanyQOC 8.8

Read investment analysis: ADTI · DSY · SKVI · TANH · GROV · IPAR · ELF · EPC · HNST · PG

Which Other Stocks Have a Similar Quality Score to BYAH?

7 companies across all industries closest to BYAH’s Quality of Company score of 2.7/10.

MTENMingteng International Corporation Inc.QOC 2.7 PAMPampa Energía S.A.QOC 2.7 EXKEndeavour Silver Corp.QOC 2.7 ABLVAble View Global Inc.QOC 2.7 NSRXNasus Pharma Ltd.QOC 2.7 TSEMTower Semiconductor Ltd.QOC 2.7 NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MTEN · PAM · EXK · ABLV · NSRX · TSEM · NVDA

What Else Do Investors Ask About Park Ha Biological Technology Co., Ltd.’s Valuation?

What is Park Ha Biological Technology Co., Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Park Ha Biological Technology Co., Ltd. (BYAH). The Quality of Company score is 2.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BYAH overvalued or undervalued right now?

At $2.81, 0 of 0 active models suggest BYAH may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Park Ha Biological Technology Co., Ltd.'s business model in Household & Personal Products.

What does a Quality of Company score of 2.7 mean for BYAH?

Park Ha Biological Technology Co., Ltd.'s QOC of 2.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BYAH?

CirclFi analyzes BYAH with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is BYAH a value trap in 2026?

Park Ha Biological Technology Co., Ltd.'s Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Park Ha Biological Technology Co., Ltd. (BYAH) a Quality of Company score of 2.7/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/BYAH/ · Methodology

Primary sources for this BYAH valuation

Financial statements: Park Ha Biological Technology Co., Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001986247) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BYAH as of 2026-08-27; valuations recomputed 2026-08-27.